Navigation Links
Phosphagenics to Conduct a Phase 1 Transdermal Oxycodone Clinical Trial
Date:9/17/2007

MELBOURNE, Australia, Sept. 17 /PRNewswire-FirstCall/ -- Phosphagenics Limited (ASX: POH, AIM: PSG, OTCQX: PPGNY) today announced that, following successful preclinical studies, it plans to undertake a Phase 1 transdermal oxycodone clinical trial aimed at providing chronic pain sufferers with a sustained-release pain management product.

Phosphagenics has submitted all necessary documents for approval of the trial, which is to be conducted at CMAX - an independent clinical research organization located at the Royal Adelaide Hospital. The trial, which will be in up to 30 healthy volunteers, will evaluate the tolerability and safety of the novel transdermal oxycodone. The trial will begin once approval has been received, which is expected within the next six weeks.

The Company is working towards becoming the first to provide chronic pain sufferers with a patch that will provide sustained-release of oxycodone into the bloodstream. Previous clinical trials have demonstrated that Phosphagenics' patented technologies can effectively deliver opiates through the skin without causing any disruption or irritation.

Harry Rosen, Phosphagenics' President and CEO, said: "We have prioritized oxycodone over morphine in our pain management pipeline as we are in commercial discussions with several companies.

"These companies' commercial interests are focused on the license of a transdermal pain product containing oxycodone."

Dr. Esra Ogru, Executive Vice President of Research and Development at Phosphagenics, said: "Our objective is to address a large unmet need by using our technology to deliver oxycodone in a sustained-release formulation to treat pain beyond a 24 hour period."

Oxycodone, currently administered in tablet or intravenous form, in an eight to 12 hour formulation, is more potent than morphine with fewer adverse effects and its worldwide sales exceed $1 billion annually.

About Phosphagenics Limited

Phosphagenics is a
'/>"/>

SOURCE Phosphagenics Limited
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Phosphagenics Announces Positive Proof of Concept Results from Studies Utilizing Companys Dermal Drug Delivery Technology
2. Phosphagenics to Commence Phase 1b Transdermal Insulin Clinical Trial in Second Quarter
3. NicOx Provides an Update on the Phase 2a Study for NCX 1000 Conducted With Axcan
4. Isotechnikas independent data monitoring committee conducts review of phase 2b kidney transplant trial
5. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
6. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
7. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
11. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... 27, 2015 CHINA ... Senior Care, Rehabilitation Medicine and Healthcare, second to none ... will be held at Shanghai New International Expo Center ... 2015,  Implementation Suggestions on Encouraging Private Capital to Participate ... was jointly issued by the Ministry of Civil Affairs of ...
(Date:3/27/2015)... March 27, 2015 According to ... (Diagnostic Catheter (Conventional, Advanced, Ultrasound), Ablation Catheter (Cryoablation, RF, ... Indication (AF, VT, WPW) - Global Forecasts to 2019 ", ... to reach around ~$4.73 Billion by 2019 with a ... to 2019. Browse   90   ...
(Date:3/27/2015)...   Hospira, Inc. (NYSE: HSP ... world,s leading provider of injectable drugs and infusion ... of biosimilarity of its proposed biosimilar, Epoetin Hospira, ... conditionally approved name of RETACRIT™, compared to the ... data were presented at the National Kidney Foundation ...
Breaking Medicine Technology:CHINA AID, the 10th China International Exhibition of Senior Care, Rehabilitation Medicine and Healthcare to be held in April 2CHINA AID, the 10th China International Exhibition of Senior Care, Rehabilitation Medicine and Healthcare to be held in April 3CHINA AID, the 10th China International Exhibition of Senior Care, Rehabilitation Medicine and Healthcare to be held in April 4CHINA AID, the 10th China International Exhibition of Senior Care, Rehabilitation Medicine and Healthcare to be held in April 5CHINA AID, the 10th China International Exhibition of Senior Care, Rehabilitation Medicine and Healthcare to be held in April 6Electrophysiology (EP) Market Worth $4.73 Billion by 2019 2Electrophysiology (EP) Market Worth $4.73 Billion by 2019 3Electrophysiology (EP) Market Worth $4.73 Billion by 2019 4Hospira Clinical Data Shows Proposed Biosimilar, Epoetin Hospira, Demonstrates Pharmacokinetic And Pharmacodynamic Equivalence Compared To Amgen's Epogen 2Hospira Clinical Data Shows Proposed Biosimilar, Epoetin Hospira, Demonstrates Pharmacokinetic And Pharmacodynamic Equivalence Compared To Amgen's Epogen 3
(Date:3/28/2015)... Vegas, NV (PRWEB) March 28, 2015 ... may not be necessary, according to research presented today ... AOSSM ) Specialty Day. , “Our study compared results ... 25 who underwent an additional glenohumeral joint capsule release ... commented George Murrell MD, PhD, lead author from St. ...
(Date:3/28/2015)... March 28, 2015 Genomic medicine experts ... mesothelioma, revealing, for the first time, key information for ... to read the newly posted story on the ... University of British Columbia, the British Columbia Cancer Agency, ... to reveal underlying molecular alterations and mutations that can ...
(Date:3/28/2015)... 28, 2015 Lately the student-athlete ... recent changes and proposals around the NCAA. In a ... former collegiate student-athletes across a spectrum of universities and ... common challenges. The special panel consists of athletes who ... ranging from football, track and field, baseball, and volleyball. ...
(Date:3/28/2015)... 2015 Healthpointe’s otolaryngologists, medical practitioners who ... disorders, are now offering a wide variety of ... is characterized by the presence of phantom sounds or ... tinnitus is a prevalent symptom that can arise due ... non-fatal, tinnitus can impede a person’s quality of life. ...
(Date:3/28/2015)... Aliso Viejo, California (PRWEB) March 28, 2015 ... have announced a new overlay entitled Scratches 5K from ... overlay grungy scratch effects to any media inside Final ... Film Studios. “StoryBoard Corporate saves time and is an ... any media using FCPX Overlay Scratches 5K's intuitive grunge ...
Breaking Medicine News(10 mins):Health News:No Need to Delay Rotator Cuff Surgery, Study Shows 2Health News:New Genomics Research May Help Doctors Tailor Mesothelioma Treatment, According to Surviving Mesothelioma 2Health News:SCI TV Panel of Former College Athletes Discusses Student Athlete Experience 2Health News:SCI TV Panel of Former College Athletes Discusses Student Athlete Experience 3Health News:Healthpointe now Offering Tinnitus Treatments in Clinics throughout Southern California 2Health News:Pixel Film Studios Unveiled Scratches 5k for Final Cut Pro X Editors 2
... The United Nations Office on Drugs and Crimes (UNODC) fears ... Asian earthquake in Pakistan and Afghanistan might turn to drugs ... possibility, the agency has launched a series of workshops ... ,Vincent McClean, Country Representative for UNODC said that the agency ...
... Research Institute of the Mary Imogene Bassett Hospital in ... Philadelphia, Pa have found that the growth of breast ... nighttime exposure to artificial light. The study, which was ... Institute of Environmental Health Sciences, also found that the ...
... from the sweet wormwood plant may help to prevent breast ... of Washington.// Artemisinin has been used to combat malaria since ... study with fellow UW bioengineer Narendra P. Singh, said that ... to cancer cells. ,“Based on earlier studies, ...
... severe form of arthritis can be cured, according to scientists ... patients. // Those who suffer from osteoarthritis will get relief ... transplant operations will have been completed. Stem cells were used ... scientists, which is self-renewing and can also be used to ...
... that wild thrashing during sleep accompanied by cries can ... Trenkwalder said that disruptions in the rapid eye movement ... approaching Parkinson's disease, according to the German journal Psychology ... disconnected from motor controls during the R.E.M. sleep cycle, ...
... Japan on Monday told that its US subsidiary Gemini Science ... bird flu. ,Kirin Brewery Co. Ltd., Japan is ... planning for a partnership with its U.S. subsidiary but also ... the commercial market. ,After the press release regarding ...
Cached Medicine News:Health News:Artificial Light Stimulates Breast Cancer Growth In Mice: Study 2Health News:Artemisinin May Prevent Breast Cancer 2
Colloidal Gold Conjugated, Goat anti-human IgA (Alpha Chain) - 50 OD...
Polyester ribbon impregnated with conjugated Protein A - .50 OD per sq. cm....
Polyester ribbons (3) impregnated with different OD values of conjugated Protein G...
Colloidal Gold Sol, 80 nm - 12 - 15 OD, 1 ml, Gold Sol Nanoparticles - not boiled, not centrifuged...
Medicine Products: